CMA
RCUS icon

Cedar Mountain Advisors’s Arcus Biosciences RCUS Stock Holding History

Cedar Mountain Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$678 Hold
22
– – ﹤0.01% 1001
2026
Q1 		$475 Hold
22
– – ﹤0.01% 1021
2025
Q4 		$524 Hold
22
– – ﹤0.01% 598
2025
Q3 		$299 Buy
+22
New +$229 ﹤0.01% 635

Other funds holding RCUS

TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SAM
Seelaus Asset Management Chatham, New Jersey $142M AUM 48.54% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return

Cedar Mountain Advisors's RCUS Position: Q2 2026 in Review

Cedar Mountain Advisors held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 22 shares worth $678. The position accounts for ﹤0.01% of the portfolio, ranked #1001.

Cedar Mountain Advisors first reported a position in RCUS in Q3 2025 and has held it in 4 quarters since. 17 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Cedar Mountain Advisors held 22 shares of Arcus Biosciences worth $678 as of Q2 2026.
  • Cedar Mountain Advisors left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #1001 holding.
  • Cedar Mountain Advisors first reported a position in Arcus Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 17 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.